CN101538247B - Preparation method of alkaloid compound - Google Patents
Preparation method of alkaloid compound Download PDFInfo
- Publication number
- CN101538247B CN101538247B CN200810010678A CN200810010678A CN101538247B CN 101538247 B CN101538247 B CN 101538247B CN 200810010678 A CN200810010678 A CN 200810010678A CN 200810010678 A CN200810010678 A CN 200810010678A CN 101538247 B CN101538247 B CN 101538247B
- Authority
- CN
- China
- Prior art keywords
- compound
- compd
- obtains
- cells
- light gray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of medicaments and discloses an alkaloid compound and a preparation method thereof. The compound is obtained by steps of the strain culture and fermentation of streptomycete YL05A-1070(CGMCC No.2362) screened from soil on the slope of Duyang Mountain in Taihua County, Guanxi province, China, the filtration, extraction, adsorption elution and freeze drying of the fermentation liquor, and the like. The purity of the compound reaches more than 95 percent. The compound and pharmaceutically acceptable salts thereof including sulfate, hydrochloride and organic acid salt have the capacity of suppressing A549 cells, HGC-2 cells, HGC-27 cells and MCF-7 cells obviously. This capacity gives an indication that the compound has antitumor activity and can be used for developing antitumor drugs.
Description
Technical field
The invention belongs to medical technical field, relate to alkaloid compound and preparation method thereof, be specifically related to a kind of compound and its pharmacy acceptable salt with anti-tumor activity; The present invention also relates to the microbial fermentation processes and the purposes of this compound on the manufacturing antitumor drug of this compound.
Background technology
Tumour is the frequently-occurring disease and the common disease of one type of serious threat human health, and M & M is in rising trend always, has become first deadly disease at present.The cancer mortality front three is liver cancer, cancer of the stomach, lung cancer, and China is one of liver cancer country occurred frequently in the world, and sickness rate is about 1/0,000.Liver cancer is in the situation of the effective medicine of a kind of famine so far, owing to liver cancer is lacked effective control method, patient's prognosis extreme difference.Except that but 5 annual survival rates of early stage patient with operation reach 80~90%, can not patient with operation, the mean survival time to paresthesia epilepsy has only 3~4 months, and average 5 annual survival rates of the whole liver cancer cases of developing country are merely about 5%.In addition, in, a thorny problem of advanced liver cancer clinical treatment is pain caused by cancer, after the patient finally brings into use morphine class analgesic; Because its serious drug dependence; Have only the increase that continues rapidly through dosage, just can reach the lenitive effect, and continuously heavy dose of analgesic uses; Increased the weight of the burden of liver again, thereby the grade malignancy of cancer is further aggravated.Therefore, antitumor type of new medicine of exploitation just seems very urgent and necessary.
Summary of the invention
One object of the present invention is to provide a kind of antitumor type of new medicine A that is used to treat tumor disease, and its molecular formula is C
7H
9FN
2O
4, molecular weight is 216, chemical structural formula is suc as formula shown in (I).Fusing point 141-143 ℃, the outward appearance powder that is white in color, it is hydrochloride, vitriol or organic salt at pharmacy acceptable salt.
The structure of the compd A that the present invention relates to adopts the method for nucleus magnetic resonance, spectroscopy such as infrared to confirm.
Another object of the present invention provides the fermentation of this antitumor antibiotics with bacterial classification and preparation method.
Through preliminary test, compd A is at the external growth that can effectively suppress kinds of tumor cells, its IC
50In 0.9-56.7 μ mol/L scope, has notable antitumor activity.
Formula 1
Indole ketone compound A of the present invention separates to extract in the fermenting culture that obtains false light gray streptomycete Y05A-1070 (CGMCC No.:2362) the soil on Yangshan slope from Guangxi province Tai Hua county to obtain, and preparing method's concrete steps are following:
(1) the slant culture method of streptomycete Y05A-1070 (CGMCC No.:2362): slant medium is formed (1L): Zulkovsky starch 20g, NaCl 0.5g, KNO
31g, K
2HPO
40.5g, FeSO
40.01g, MgSO
4.7H
2O0.5g, agar part 20g, pH 7.0.28-30 ℃, cultivated 7 days.
(2) the seed liquor cultural method of streptomycete Y05A-1070 (CGMCC No.:2362): seed culture medium is formed (1L): analysis for soybean powder 5~15g, yeast extract paste 3~7g, glucose 10~30g, starch 10~30g, K
2HPO
40.1-1.0g, (NH
4)
2SO
40.1-3.0g, MgSO
4.7H
2O 0.1-0.5g, CaCO
30.1-5.0g pH 7.2.Triangle shakes bottled amount 20-60%, rotating speed 100-250 rev/min, 28-32 ℃, cultivates 20-48 hour.
(3) fermentation process of streptomycete Y05A-1070 (CGMCC No.:2362): fermention medium is formed (1L): peanut powder 10-25g, yeast extract paste 5-30g, glucose 0.5-30g, peptone 0.1-10g, (NH
4)
2SO
40.1-10g, KCl 0.1-3g, pH 7.0.Fermentor tank loading amount 20-60%, inoculum size 3-12%, 28-32 ℃, cultivated 5-7 days by rotating speed 100-250 rev/min.After the fermentation ends, tunning obtains mycelium and ferment filtrate two portions after filtering through plate-and-frame filter press.
(4) the mycelium part that obtains of step (3),
(a) with clear water wash 2-3 all over after, squeeze out most of moisture, airing under the normal temperature;
(b) mycelium is with the methanol extraction several, and the extract concentrating under reduced pressure obtains medicinal extract;
(c) medicinal extract disperses with zero(ppm) water, with ethyl acetate extraction for several times, separates and recrystallization purifying through 100-200 order silicagel column (moving phase is chloroform-ETHYLE ACETATE gradient elution), obtains compd A.
The external growth that can effectively suppress kinds of tumor cells of compound through the present invention's preparation has notable antitumor activity.
Used false light gray streptomycete (Streptomyces pseudogriseolus) Y05A-1070 of the present invention has been preserved in China Committee for Culture Collection of Microorganisms common micro-organisms center (Datun Road, Chaoyang District, Beijing City Institute of Microorganism, Academia Sinica); Preserving number is CGMCC No.:2362), preservation day is on January 25th, 2008.
Embodiment
The preparation of embodiment 1 compd A
(1) the slant culture method of streptomycete Y05A-1070 (CGMCC No.:2362): slant medium is formed (1L): Zulkovsky starch 20g, NaCl 0.5g, KNO
31g, K
2HPO
40.5g, FeSO
40.01g, MgSO
4.7H
2O 0.5g, agar part 20g, pH 7.0.28-30 ℃, cultivated 7 days.
(2) the seed liquor cultural method of streptomycete Y05A-1070 (CGMCC No.:2362): seed culture medium is formed (1L): analysis for soybean powder 5~15g, yeast extract paste 3~7g, glucose 10~30g, starch 10~30g, K
2HPO
40.1-1.0g, (NH
4)
2SO
40.1-3.0g, MgSO
4.7H
2O 0.1-0.5g, CaCO
30.1-5.0g pH 7.2.Triangle shakes bottled amount 20-60%, rotating speed 100-250 rev/min, 28-32 ℃, cultivates 20-48 hour.
(3) fermentation process of streptomycete Y05A-1070 (CGMCC No.:2362): fermention medium is formed (1L): peanut powder 10-25g, yeast extract paste 5-30g, glucose 0.5-30g, peptone 0.1-10g, (NH
4)
2SO
40.1-10g, KCl 0.1-3g, pH 7.0.Fermentor tank loading amount 20-60%, inoculum size 3-12%, 28-32 ℃, cultivated 5-7 days by rotating speed 100-250 rev/min.After the fermentation ends, tunning obtains mycelium and ferment filtrate two portions after filtering through plate-and-frame filter press
(4) the mycelium part that obtains of step (3),
(a) with clear water wash 2-3 all over after, squeeze out most of moisture, airing under the normal temperature;
(b) mycelium is with the methanol extraction several, and the extract concentrating under reduced pressure obtains medicinal extract;
(c) medicinal extract disperses with zero(ppm) water, with ethyl acetate extraction for several times, separates and recrystallization purifying through 100-200 order silicagel column (moving phase is chloroform one ETHYLE ACETATE gradient elution), obtains compd A.
The experimental data of compd A: outward appearance is a white powder, m.p.141-143.Be slightly soluble in benzene, chloroform, ether equal solvent, water-soluble, ethanol, methyl alcohol.MS(m/z):216。IRυ/cm
-1(KBr):1761(υ
C=O),1724(υ
C=O),1657(υ
C=O)。
1H-NMR(CDCl
3)δ:1.31(3H,t,J=7.2Hz,-CH
3),4.26(2H,q,J=7.2HZ,-COOCH
2-),4.68(2H,s,-CH
2N<C-9),7.32(1H,d,C-H,J=3.0Hz),9.93(1H,br?s,H-N<)。
The anti-tumor activity of embodiment 2 MTT reduction method detection compound A
1. material:
1.1 four Cuo salt (MTT): with the phosphate buffered saline buffer (PBS) of 0.01M dissolving MTT (3-(4,5-dimethythiaZol z-yl) 2,5-diphenyltetrazolium bromide, SIGMA) final concentration 5mg/mL, filtration sterilization, 4 ℃ keep in Dark Place after the packing.
1.2 the preparation of target cell (is example with the A549 cell): from liquid nitrogen container, take out the frozen pipe of human lung carcinoma cell line A549 cell, insert rapidly in 37 ℃ of water-baths, do not stop to shake and make it to dissolve rapidly, aseptic technique moves in the centrifuge tube; To 10mL, the centrifugal 5s of 1000rpm abandons supernatant to add full nutrient solution (RPMI1640 (Gibcol BRL company) that contains 10% calf serum); Repeat above operation once; Move in the culturing bottle 5%CO after making the cell mixing with the piping and druming of full nutrient solution
2, 37 ℃ of cultivations; The observation of cell growing state is in time changed nutrient solution, divides bottle.The cell in vegetative period of taking the logarithm, trysinization, adjustment cell count to 1 * 10
5/ mL; Cell suspension is joined in 96 orifice plates, and each hole adds A549 cell 100 μ L (1 * 10
5/ mL), 5%CO
2, cultivate 8hr for 37 ℃.Add different concns B6-9 (using full nutrient solution preparation) solution 100 μ L, contrast adds full nutrient solution 100 μ L, continues to cultivate 48hr.Every hole adds each 10 μ L of MTT solution, continues to cultivate 4hr.Remove nutrient solution, every hole adds DMSO100 μ L, and the 5-10min that vibrates gently makes the particle dissolving.Use the enzyme linked immunological appearance to measure every hole OD value under the 570nm.Calculate tumor cell destruction and inhibiting rate,, try to achieve IC with the logarithm mapping of inhibiting rate to drug level
50Lung cancer cell line A549, hepatoma cell strain HepG-2, stomach cancer cell line HGC-27, the TP of breast cancer cell strain MCF-7 is the same.
Tumor cell destruction %=[the average OD value that (the average OD value of average OD value-dosing group mensuration that control group is measured)/control group is measured] * 100%
1.3 experimental result
Experimental result shows that compd A all can effectively suppress lung cancer cell line A549, hepatoma cell strain HepG-2, stomach cancer cell line HGC-27, the growth of breast cancer cell strain MCF-7.Compd A is to the IC of these cancer cells
50Value (μ mol/L) is seen table 1.
The cell in vitro poison test-results (IC of table 1 B6-9
50μ mol/L)
Cell strain | Compd A |
Lung cancer cell line A549 | ?0.9 |
Hepatoma cell strain HepG-2 | ?15.3 |
Stomach cancer cell line HGC-27 | ?31.0 |
Breast cancer cell strain MCF-7 | ?56.7 |
Claims (1)
1. the preparation method of an alkaloid compound A; Described compd A structural formula is following; It is characterized in that: this method comprises that cultivation can produce the culture condition of false light gray streptomycete (Streptomyces pseudogriseolus) the Y05A-1070CGMCC No.2362 of said compd A; And from fermented liquid, reclaim resulting compd A, its concrete steps are following:
(1) the slant culture method of false light gray streptomycete Y05A-1070CGMCC No.2362: the 1L slant medium is formed: Zulkovsky starch 20g, NaCl 0.5g, KNO
31g, K
2HPO
40.5g, FeSO
40.01g, MgSO
4.7H
20 0.5g, agar powder 20g, pH7.0, cultivated 7 days by 28-30 ℃;
(2) the seed liquor cultural method of false light gray streptomycete Y05A-1070 CGMCC No.2362: the 1L seed culture medium is formed: analysis for soybean powder 5~15g, yeast extract paste 3~7g, glucose 10~30g, starch 10~30g, K
2HPO
40.1-1.0g, (NH
4)
2SO
40.1-3.0g, MgSO
4.7 H
2O 0.1-0.5g, CaCO
30.1-5.0g pH7.2, triangle shake bottled amount 20-60%, rotating speed 100-250 rev/min, 28-32 ℃, cultivate 20-48 hour;
(3) fermentation process of false light gray streptomycete Y05A-1070 CGMCC No.2362: the 1L fermention medium is formed: peanut powder 10-25g, yeast extract paste 5-30g, glucose 0.5-30g, peptone 0.1-10g, (NH
4)
2SO
40.1-10g, KCl 0.1-3g, pH7.0, fermentor tank loading amount 20-60%; Inoculum size 3-12%, 28-32 ℃, cultivated 5-7 days by rotating speed 100-250 rev/min; After the fermentation ends, tunning obtains mycelium and ferment filtrate two portions after filtering through plate-and-frame filter press;
(4) the mycelium part that obtains of step (3),
(a) with clear water wash 2-3 all over after, squeeze out most of moisture, dry under the normal temperature;
(b) mycelium is with the methanol extraction several, and the extract concentrating under reduced pressure obtains medicinal extract;
(c) medicinal extract disperses with zero(ppm) water, with ethyl acetate extraction for several times, through 100-200 order silicagel column, is the eluent gradient wash-out with chloroform one ETHYLE ACETATE, separates and recrystallization purifying, obtains compd A
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810010678A CN101538247B (en) | 2008-03-17 | 2008-03-17 | Preparation method of alkaloid compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810010678A CN101538247B (en) | 2008-03-17 | 2008-03-17 | Preparation method of alkaloid compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101538247A CN101538247A (en) | 2009-09-23 |
CN101538247B true CN101538247B (en) | 2012-08-29 |
Family
ID=41121663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810010678A Expired - Fee Related CN101538247B (en) | 2008-03-17 | 2008-03-17 | Preparation method of alkaloid compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101538247B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104911121B (en) * | 2015-04-07 | 2017-12-15 | 浙江省农业科学院 | False light gray streptomycete and its microbial bacterial agent and application |
CN110467574A (en) * | 2019-07-17 | 2019-11-19 | 蒋周倩 | Compound adamantane acid -5 FU 5 fluorouracil methyl esters synthesis and application |
CN113292574B (en) * | 2020-02-21 | 2022-05-03 | 四川大学 | Chiral polycyclic tropane compounds, preparation method and application thereof |
-
2008
- 2008-03-17 CN CN200810010678A patent/CN101538247B/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
Toshio NAGASE et al..Application of the Benzyloxycarbonyloxymethyl Moiety to a Protective Group of 5-Fluorouracil. Selective Alkylation of Amide Nitrogen of the Uracil Ring.《CHEMISTRY LETTERS》.1988,1381-1384. * |
孙昌俊 等.3-N-取代-5-氟脲嘧啶的制备新方法.《合成化学》.1996,第4卷(第4期),293-295. * |
孙昌俊 等.5-氟尿嘧啶衍生物的合成及其抗肿瘤活性.《中国药物化学杂志》.1998,第8卷(第2期),93-95. * |
Also Published As
Publication number | Publication date |
---|---|
CN101538247A (en) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102224861A (en) | Health preserving fungi tea | |
CN103665080B (en) | Triterpenoid compounds and application thereof in diabetes treatment drugs | |
CN102731365B (en) | Hericium erinaceum biological micro-molecules for inhibiting helicobacter pylori and use of hericium erinaceum biological micro-molecules in treatment of digestive tract diseases | |
CN103865808A (en) | Novel anti-tumor application of penicillium enol A1 from penicillium citrinum | |
CN104531540A (en) | Antitumor application of penicillium enol A2 from penicillium citrinum | |
CN101104864B (en) | Method for preparing epothilones B | |
CN101538247B (en) | Preparation method of alkaloid compound | |
CN101628931B (en) | Antitumor antibiotics, pharmaceutically acceptable salts thereof, preparation method thereof and use thereof | |
CN102293122B (en) | Cultivating method for cordyceps militaris by using manyprickle acathopanax root | |
CN109810113A (en) | A kind of alkaloid compound and the preparation method and application thereof | |
CN102178701B (en) | Preparation method of polysaccharide composite with antitumor activity | |
CN101407767A (en) | Method for producing Chinese caterpillar fungus by fermentation | |
CN102911877A (en) | Marine fungi cladosporium sphaerospermum and application thereof | |
CN101538239B (en) | Antitumor antibiotic and preparation method thereof | |
CN1212387C (en) | Fine rod bundle spore SX-1 separated and cultured from cordyceps and its saparation, culture process and use | |
CN102531906B (en) | Application of natural compound P21 in inhibition of reproductive growth of tumor cell | |
CN109966322A (en) | A kind of two-way solid fermentation object of gecko-Paecilomyces cicadae and the preparation method and application thereof | |
CN100430361C (en) | Quinone compounds and its preparation method and antineoplastic use | |
JP3719689B2 (en) | Novel substance triprostatin, process for producing the same, cell cycle inhibitor and antitumor agent | |
CN101362745A (en) | Xanthenes compounds, preparation method and application thereof in antitumor | |
CN105274175A (en) | Solid fermentation process and antitumor activity of Fomitopsis pinicola | |
CN110218174B (en) | Compound and preparation method and application thereof | |
CN102584680A (en) | Aspochalasin U and preparing method and application thereof | |
CN103421849B (en) | A kind of compound with antibacterial activity and preparation method thereof | |
CN115990162B (en) | Application of 4-hydroxy-2-pyridone alkaloid in preparation of medicines for treating gastric cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120829 Termination date: 20170317 |
|
CF01 | Termination of patent right due to non-payment of annual fee |